Biotech News

Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences (DTIL)Precision BioSciencesEarnings

- PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting ® 2026 on November 8; data abstract scheduled for release November 5 - - Dosed first patient with PBGENE-DMD at Arkansas Children's Hospital in the Phase 1/2 FUNCTION-DMD study; initial safety data

Related news

Precision BioSciences

ARCUS Gene Editing Platform Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material. PBGENE-HBV PBGENE-HBV is a wholly...

Recent company news

Stock data

Close
6.91 USD
Market cap
163.07M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States